Floatz logo

Nevirapine Anhydrous

HIV Wasting Syndrome

National Institute of Allergy and Infectious Diseases (NIAID)Small moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the HIV Wasting Syndrome cohort.

Asset / SponsorPhaseRating
2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 4BB
Megestrol Acetate Impurity B
Endo USA Inc., a Keenova Therapeutics Company
Phase 2BB
Serostim
EMD Serono
Phase 3B
Testosterone Undecylate
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2B
Atazanavir
National Institute of Allergy and Infectious Diseases (NIAID)
N/AD
Lopinavir
National Institute of Allergy and Infectious Diseases (NIAID)
N/AD
NORVIR
National Institute of Allergy and Infectious Diseases (NIAID)
N/AD
Abacavir
National Institute of Allergy and Infectious Diseases (NIAID)
N/AD

Same molecule, other indications

Nevirapine Anhydrous is also rated in:

HIV infectious diseaseDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
lipodystrophyDormant
BBB
Indicative · Phase 4
75 / 100
View asset →
inherited lipid metabolism disorderDormant
BB
Indicative · Phase 4
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →